Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Baricitinib vs TNF Inhibitors in Rheumatoid Arthritis
NCT03915964Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 24
01
Overview
A Phase 4 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Apr 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03915964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915964.